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Sasa quelpaertensis leaf extract regulates
microbial dysbiosis by modulating the
composition and diversity of the
microbiota in dextran sulfate sodium-
induced colitis mice
Yiseul Yeom1, Bong-Soo Kim2, Se-Jae Kim3 and Yuri Kim1*
Abstract
Background: Inflammatory bowel diseases (IBD) are related to a dysfunction of the mucosal immune system and
they result from complex interactions between genetics and environmental factors, including lifestyle, diet, and the
gut microbiome. Therefore, the effect of Sasa quelpaertensis leaf extract (SQE) on gut microbiota in a dextran sulfate
sodium (DSS)-induced colitis mouse model was investigated with pyrosequencing of fecal samples.
Methods: Three groups of animals were examined: i) a control group, ii) a group that was received 2.5% DSS in
their drinking water for 7 days, followed by 7 days of untreated water, and then another 7 days of 2.5% DSS in their
drinking water, and iii) a group that was presupplemented with SQE (300 mg/kg body weight) by gavage for two
weeks prior to the same DSS treatment schedule described in ii.
Results: SQE supplementation alleviated disease activity scores and shortened colon length compared to the other
two groups. In the DSS group, the proportion of Bacteroidetes increased, whereas that the proportion of Firmicutes
was decreased compared to the control group. SQE supplementation recovered the proportions of Firmicutes and
Bacteroidetes back to control levels. Moreover, the diversity of microbiota in the SQE supplementation group higher
than that of the DSS group.
Conclusion: SQE was found to protect mice from microbial dysbiosis associated with colitis by modulating the
microbial composition and diversity of the microbiota present. These results provide valuable insight into
microbiota-food component interactions in IBD.
Keywords: Sasa quelpaertensis leaf extract, Inflammatory bowel disease, Dextran sulfate sodium, Gut microbiota
Background
Inflammatory bowel diseases (IBD), including Crohn’s
disease (CD) and ulcerative colitis (UC), are chronic and
recurrent inflammatory disorders with uncertain etiology
[1]. IBD are generally accompanied by abdominal pain,
weight loss, and diarrhea, and can result in complete ob-
struction of the gastrointestinal (GI) tract [2]. Worldwide,
the incidence and prevalence of IBD have increased over
the past few decades. To date, the precise pathogenesis of
IBD remains unclear, although dysfunction of the immune
system due to interactions between a host’s response to
microbial flora in the gut may be one of the main factors
that contribute to these diseases [3].
Hunan gut microbiota consists of more than 100 tril-
lion microorganisms, which is ten times more than the
total number of human cells in the body [4]. In general,
a fetus grows in a sterile environment in the uterus.
Then, after birth, gut colonization starts rapidly and it is
influenced by a variety of factors, including diet, antibi-
otics, and stress [5]. Gut microbiota have diverse and
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useful functions in energy balance, glucose metabolism,
drug metabolism, and inflammation in a host [6]. How-
ever, when an imbalance in normal gut microbiota
occurs, this is known as dysbiosis. Dysbiosis underlies
the pathogenesis of numerous diseases, including IBD,
colorectal cancer, and metabolic syndrome in connec-
tion with host metabolism [7, 8]. For obese individ-
uals, their intestinal microbiota contains a higher
proportion of Firmicutes, and a lower proportion of
Bacteriodetes compared to lean individuals [9, 10]. In-
sulin sensitivity and plaque synthesis in blood vessels
can also be altered by gut microbiota [9, 11]. Further-
more, changes in the population and metabolism of
the diverse bacteria population in a GI tract can
affect systemic inflammation and the function of neu-
rotransmitters in the brain [12, 13].
Gut microbiota plays a critical role in anti-inflammatory
and immune-regulatory function, and thus, potentially
represent an attractive IBD therapy. Various therapies that
target restoration of the gut microbiota by altering their
composition have been suggested, including fecal micro-
biota transplantation, probiotics, prebiotics, antibiotics,
and dietary intervention. Recent interest in the dietary
phytonutrients that are present in natural herbs has led to
investigations of their potential impact on human health.
For example, the polyphenols present in various natural
herbs have been reported to modulate the composition
and numbers of gut microbiota and to indirectly influence
metabolism and the bioavailability of gut microbiota [14].
Another key benefit that has been found is an absence of
undesirable side effects. Thus, gut microbiota may repre-
sent a potential therapeutic strategy for IBD and may help
maintain intestinal function [15].
Sasa quelpaertensis Nakai is an edible dwarf bamboo
grass that inhabits the area surrounding Mt Halla on
Jeju Island in Korea. Its leaf extract has been reported to
mediate various health promoting properties, including
anti-inflammation, anti-cancer effects, and anti-obesity
effect [16–18]. Sasa quelpaertensis leaves extract (SQE)
is a mixture of polysaccharides, amino acids, and poly-
phenols, including p-coumaric acid and tricin, and has
exhibited anti-inflammatory and anti-obesity effects [19,
20]. In particular, SQE has been found to mediate anti-
inflammatory effects by regulating inflammatory media-
tors such as nitric oxide, tumor necrosis factor α, and
COX-2 both in vivo and in vitro [17]. However, there is
limited evidence regarding the effect of SQE on gut
microbiota during inflammation.
Therefore, in the present study, the ability of SQE
to regulate inflammation by modulating microbial
composition in a dextran sulfate sodium (DSS)-in-
duced colitis animal model was evaluated using high-




SQE was prepared as previously described [17]. Sasa
quelpaertensis Nakai voucher specimen has been depos-
ited in a publicly available herbarium name as HALLA
ARBORETUM HERBARIUM and deposit number is
HA006630. Briefly, collected Sasa quelpaertensis Nakai
leaves (1 kg) were collected from Mt. Halla on Jeju Is-
land, South Korea and were washed twice with deionized
water. The leaves were then dried and extracted with 70%
ethanol for 48 h at room temperature. After the SQE was
filtered, it was concentrated with a rotary evaporator under
reduced pressure and freeze-dried. The resulting SQE ex-
tract was crushed into a powder and stored at - 20 °C until
needed. Previously, we have reported that p-coumaric acid
and tricin were two major bioactive compounds in SQE
and determined the concentrations of these compounds
using high performance liquid chromatography (HPLC)
2695 Alliance System (Waters Corp., Mildford, MA, USA).
The concentrations of each p-coumaric acid and tricin were
1.13 and 0.82 mg/g [17].
Induction of DSS-induced colitis in mice
Five-week-old male C57BL/6 mice were purchased (Cen-
tral Lab, Animal Inc., Seoul, Korea) and maintained
under standard laboratory conditions: 22 ± 2 °C, 50 ±
5% humidity, and a 12 h/12 h light/dark cycles. Animals
received a modified American Institute of Nutrition
(AIN)-93G pellet diet (Unifaith, Inc., Seoul, Korea). Diet
composition was provided in Table 1. To confirm their
health status, all mice were housed for 1 week before be-
ing randomized into three groups (n = 6/group).
The three experimental groups included: i) mice receiving
a standard diet and normal drinking water (control), ii) mice
receiving 2.5% DSS (DSS), and iii) mice receiving DSS +
SQE [300 mg/kg body weight (b.w.)] (SQE). The DSS and
Table 1 Dietary composition for the experiment








Mineral mix, AIN-93Ga) 35
Vitamin mix, AIN-93G 10
Cholin Bitartrate 2.5
t-butylhydroquinone 0.014
a)Mineral mixture and vitamin mixture were prepared according to
AIN-93G diet
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SQE groups received 2.5% DSS (molecular weight: 36 – 50
kDa; MP Biomedicals, Costa Mesa, CA, USA) in their
drinking water for 7 d, followed by 7 d of untreated drinking
water, and then another 7 d of 2.5% DSS in their drinking
water. The SQE group mice received a daily oral dose of
SQE for 14 d prior to DSS treatment. During the experi-
mental period, body weight and diet intake were recorded
twice a week. After five weeks, all of the mice were sacri-
ficed. Animal care and experimental protocols for this study
were approved by the Animal Care and Use Committee of
Ewha Womans University (IACUC approval no: IACUC
14-070).
Disease activity index (DAI)
DAI scoring was measured from the start of DSS adminis-
tration until the end of the experimental period as de-
scribed previously [17]. DAI scores were determined
based on weight loss, stool consistency, and fecal bleeding.
Stool consistency was evaluated according to the presence
of loose feces and watery diarrhea. Fecal bleeding was
scored as normal, slightly bloody, and blood in whole
colon compared to the control group.
Genomic DNA extraction
To analyze gut microbiota analysis, fecal samples were
collected at 19 d after the start of the DSS treatment.
Metagenomic DNA was extracted with Fast DNA SPIN
Kits (MP BIO, Santa Ana, CA, USA), according to the
manufacturer’s instructions. The resulting metagenomic
DNA samples were dissolved in 50 μl of elution buffer
and stored at - 20 °C until needed. DNA concentrations
were determined based on optimal density value ob-
tained at 260 nm. Sample purity was determined based
on the ratio of the absorbance values obtained at 260
nm and 280 nm.
Pyrosequencing analysis of gut microbiota based on the
16S rRNA gene
The 16S rRNA gene (targeted V1-V3 regions) was amp-
lified from the extracted DNA using barcoded primers
(27 F and 518R). The resulting PCR products were con-
firmed by gel electrophoresis and purified. Sequencing
of the amplicons was conducted using a Roche/454 GS
Junior system (ChunLab, Inc., Seoul, Korea). Data ana-
lysis was performed according to previously described
method [21]. Each sample was sorted according to a
unique barcode. Low quality reads (average quality score
< 25 or read length < 300 bp) did not undergo further
analysis. The primer sequences were trimmed and clus-
tered for correcting sequencing errors. The taxonomic
positions of the representative sequences for each cluster
were identified using the EzTaxon-e database [22].
Chimeric sequences were removed using the UCHIME
program [23] and the diversity indices were calculated
with the Mothur program [24]. The pyrosequences pre-
sented in this study are available in the EMBL SRA data-
base under the study PRJEB13815 (http://www.ebi.ac.uk/
ena/data/view/PRJEB13815). The operational taxonomic
unit (OTUs) were mathematically defined as having a
3% sequence distance (e.g. 97% similarity). Diversity and
richness were calculated using the Cluster Database at
High Identity with Tolerance (CD-HIT). Alpha diversity
indices such as Chao1 and Shannon diversity were used
to estimate species richness using the Mothur program
and the matrix of Fast UniFrac. Principal coordinate
analysis (PCoA) was used to represent the relationships
between samples based on calculations of Jaccard abun-
dance similarity and Bray-Curtis similarity [24, 25].
Statistical analysis
Statistical analyses were performed using GraphPad
PRISM software (GraphPad Software, SanDiego, CA,
USA). Data presented are the mean ± standard error of
the mean (SEM) for each group. For multiple compari-
sons, one-way analysis of variance (ANOVA) with
Newman-Keuls’s post-hoc test was used. A P-value less
than 0.05 was considered statistically significant.
Result
DAI and colon length
DAI scores were significantly increased up to day 5 and
peaked on day 19 in the DSS group compared to the con-
trol group (Fig. 1a). The increase in DAI values was based
on the observed incidence of diarrhea, weight loss, and
bloody stools. In contrast, the DAI scores of the SQE
group were significantly attenuated by 61.9% at day 5 and
by 77.4% at day 19 compared to the DSS group (p < 0.05
in each case). Moreover, the DAI score for the SQE group
was comparable to that of the control group.
Since severity of DSS-induced colitis was found to be
associated with a shorter colon length [26], whole colon
tissues were isolated from each group and their lengths
were and compared. The mean colon length of the DSS
group was 27% shorter than the mean colon length of
the control group, and SQE supplementation signifi-
cantly attenuated shortening of the colon compared with
the DSS group (Fig. 1b).
OTUs and diversity estimates for fecal microbiota
The average numbers of analyzed sequence reads were
5310 ± 1519 for the control group and 4722 ± 1092 for
the DSS group, and 4744 ± 1092 for the SQE group
(Table 2). The Good’s coverages of all the samples were
greater than 0.97. The number of observed OTUs was
444.83 ± 66.84 for the control group, 256.33 ± 65.64 for
the DSS group, and 404.17 ± 178.21 for the SQE group.
The number of observed OTUs was significantly lower
for the DSS group compared with the control group by
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42.4%, while the number of OTUs in the SQE group
tended to be greater than the number of OTUs for the
DSS group (57.7%). Similarly, the number of estimated
OTUs (Chao1) in the DSS group was significantly lower
than those for the control group (p < 0.05, 44.3%), while
those for the SQE group were higher compared to the
DSS group (p < 0.05, 62.2%). The Shannon diversity in-
dices for the control group were also significantly higher
than those for the DSS group, yet were similar to those
of the SQE group. Taken together, these results indicated
that the diversity of gut microbiota in the DSS group
were more diverse than the gut microbiota of the con-
trol and SQE groups.
Comparison of gut microbiota
To compare microbial community members among the
three groups, clustering patterns based on a weighed
pairwise Fast UniFrac analysis was determined (Fig. 2).
The gut microbiota obtained from the DSS group was
distinct from those of the control and SQE group, and
the gut microbiota of the SQE group were closer to the
control group in PCoA plot.
Comparison of gut microbiota composition with
pyrosequencing
To analyze gut microbiota, fecal samples were collected
at day 19 d after the start of the DSS treatment and they
were analyzed using pyrosequencing. Differences in the
microbiota among the groups were compared at the
phylum level (Fig. 3). DSS treatment greatly increased
the levels of Bacteroidetes by 44.9%, and decreased the
levels of Firmicutes by 34.4% compared to the control
group (Fig. 3a and b). Correspondingly, the ratio of
Bacteroidetes to Firmicutes in the gut microbiota was
higher for the DSS group compared to the control group
(Fig. 3c). However, following SQE supplementation, the
proportions of Bacteroidetes and Firmicutes returned to
control levels. Moreover, the ratio of Bacteroidetes to
Firmicutes decreased following SQE supplementation. In
contrast, the levels of Proteobacteria and Deferribacteres
did not significantly different among the three groups.
Gut microbiota were also compared at the class by
heatmap analysis (Fig. 4a). The bacteria were divided
into a major class and a minor class (representing < 10%
of the total proportion). Clostridia, Bacteroidia, and Ery-
sipelotrichi constituted the major class of bacteria de-
tected, whereas Deltaproteobacteria, Deferribacteres_c,
Gammaproteobacteria, Verrucomicrobiae, and Betapro-
teobacteria constituted the minor class of bacteria. The
proportion of Bacteroidia and Gammaproteobacteria
were 50.3% and 4.1% in the DSS group, while Clostridia
was decreased by 62.2% in the DSS group compared
with the control group (Fig. 4b and c). In the SQE
group, the proportion of Clostridia was more than two
Fig. 1 DAI scores and colon length in the DSS-induced colitis. a DAI values were evaluated based on observed changes and scoring of body
weight loss, stool consistency, and fecal bleeding. b, Colon length was measured and compared among the control, DSS, and SQE groups. Data
shown are the means ± SEM and were analyzed by one-way ANOVA and Newman-Keuls’s post hoc test (p < 0.05); n = 6 mice per group
Table 2 Summary of diversity indices obtained from pyrosequencing results
Control DSS SQE
Analyzed sequence reads (avg.) 5310 ± 1519 4722 ± 1092 4744 ± 1096
Goods Coverage 0.97 ± 0.01 0.98 ± 0.01 0.97 ± 0.01
Observed OTUs 444.83 ± 66.84 a 256.33 ± 65.64 b 404.17 ± 178.21 ab
Chao1 estimators 657.94 ± 91.98 a 366.26 ± 109.76 b 594.05 ± 259.98 a
Shannon diversity index 4.75 ± 0.19 a 3.96 ± 0.31b 4.52 ± 0.69 a
Values are mean ± SD
Significantly different by one – way ANOVA and Newman-Keuls’s post hoc test among the three groups (p < 0.05); n = 6 mice per group.
abcFor a given column, data not sharing a common superscript letter significantly differ
Yeom et al. BMC Complementary and Alternative Medicine  (2016) 16:481 Page 4 of 11
Fig. 2 Principal coordinate analysis (PCoA) plot. PCoA was used to determine clustering patterns among the control, DSS, and SQE groups (n = 6
mice/group). Similarities between the communities were calculated by employing Fast UniFrac analysis
Fig. 3 Composition of the gut microbiota at the phylum level. a The composition of gut microbiota at the phylum level. b, c Changes in the
proportion of major class (b) and minor class (c) bacterial at the phylum level among the control, DSS, and SQE groups. c Relative abundance of
phylum level of minor proportion of bacteria in control, DSS, and SQE group. Data shown are the means ± SEM and were analyzed by one-way
ANOVA and Newman-Keuls’s post hoc test (p < 0.05); n = 6 mice per group
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times higher, and the proportion of Bacteroidia and
Gammaproteobacteria were significantly lower
(83.6%), compared to the DSS group. Moreover, both
Bacteroidia and Gammaproteobacteria almost recov-
ered to control levels.
Colitis led to the dysbiosis of the intestinal microbiota
in the DSS treated mice at the family level, similar to the
observations made at the phylum and class levels. When
differences in the microbiota at the family level were
compared (Fig. 5a). Lachnospiraceae, Bacteroidaceae,
and Ruminococcaceae were found to be the dominant
bacteria in all three group. DSS treatment decreased the
proportions of Lachnospiraceae (68.4%) and Ruminococ-
caceae (57.8%), and increased the proportion of Bacter-
oidaceae two-fold compared to the control group
(Fig. 5b). With SQE supplementation, the proportion of
all three bacteria returned to the levels of control group.
When the bacteria were divided into a major family and
a minor family of bacteria, Lachnospiraceae, Bacteroida-
ceae, and Ruminococcaceae constituted the are major
family of bacteria, while Coprobacillus, Prevotellaceae,
and Enterobacteriaceae constituted the minor family of
bacteria (representing less than 10% of the total
proporation). Among the minor bacteria, the proportion
of Coprobacillus, and Enterobacteriaceae greatly in-
creased following DSS treatment compared with the
control group, and these increases were suppressed fol-
lowing SQE supplementation (Fig. 5c). In contrast, the
abundance of Prevotellaceae and Streptococcaceae did
not significantly differ among the three groups.
At the genus level, the proportion of Clostridium,
Bacteroides, and Enterobacter significantly increased fol-
lowing DSS treatment compared to the control group,
yet they decreased to control levels following SQE sup-
plementation (Table 3). In contrast, the proportion of
Hungarella and Alistipes significantly decreased follow-
ing DSS treatment, while SQE supplementation tended
to increase the proportion of these bacteria. At the
species level, the proportion of Bacteroides acidifaciens
(p < 0.001), Clostridium cocleatum (p < 0.001), and un-
classified Bacteroides (p < 0.01) were significantly higher
in the DSS group compared to the control group. How-
ever, following SQE supplementation, the proportion of
these bacteria decreased back to the proportions ob-
served in the control group (Table 4). These results sug-
gest that SQE supplementation attenuates intestinal
Fig. 4 Taxonomy composition of the gut microbiota at the class level. a A heatmap analysis of the class levels for the three experimental groups.
Genomic DNA was extracted from the fecal samples obtained 19 d after the start of DSS treatment. The samples were analyzed for their bacterial
composition based on pyrosequencing of 16S rRNA. The data are represented by red and green colors and the cut-off value was set at 5% (b, c)
Relative abundance of the major gut microbiota at the class levels. Data shown are the means ± SEM and were analyzed by one-way ANOVA
and Newman-Keuls’s post hoc test (p < 0.05); n = 6 mice per group
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bacteria dysbiosis by regulating the bacteria compos-
itional changes in bacteria that are associated with DSS-
induced colitis in mice.
Discussion
The human gut contains a large population of diverse
and complex enteric microbiota. Tremendous changes
in the diversity and composition of this community, as
well as the metabolic function of the gut microbiota,
have been related to IBD [27, 28]. In particular, gut
microbiota have been identified as a critical factor in
IBD. Correspondingly, short-term antibiotic treatment
for IBD patients have been used to suppress intestinal
inflammation [29, 30]. Using murine model in gut
microbiota study has been allowed functional and meta-
bolic research on host-microbe interactions, and has
brought more insights into the pathological mechanisms
of IBD [31]. In colitis mouse model, the major gut
microbiota shifted and gut bacterial diversity was re-
duced similar to those found in human IBD [32, 33].
Previously, it was reported that SQE treatment modu-
lated the levels of proinflammatory markers, while also
regulated the activation of nuclear factor κB and oxidative
stress, in animal models of DSS-induced colitis [17, 34]. In
the present study, the goal was to understand the effect of
SQE on dysbiosis of microbiota in DSS-induced colitis.
Therefore, overall differences in the microbial community,
as well as modifications of microbiota composition after
SQE treatment were investigated by using barcoded pyro-
sequencing of the 16S rRNA gene. The results obtained
demonstrate that the microbial community profiles of the
experimental groups examined were altered by DSS treat-
ment, and dysbiosis of gut microbiota was improved with
SQE supplementation.
In animal models of IBD, DAI value and colonic length
are key indicators for evaluating the severity of colitis
[35, 36]. Consistent with the results of a previous study
[17], SQE supplementation attenuated the severity of
colitis by lowering the DAI value and extending the
length of the colon. In contrast, changes in the colon
epithelium and higher DAI values characterized in the
DSS group compared with the control group,
Modification to the composition of a microbial com-
munity may involve changes in diversity and in bacterial
metabolism. Furthermore, an imbalance between obli-
gate anaerobic bacteria and facultative anaerobic bacteria
can occur, and this is related to the inflammation
process [37, 38]. For example, Ott et al. reported that a
Fig. 5 Composition of gut microbiota at the family level. a The composition of gut microbiota at the family level. b Relative abundance of the
dominant family level in samples of control and DSS, SQE group. c Relative abundance of family level of minor proportion of bacteria in control, DSS,
and SQE groups. Data shown are the means ± SEM and were analyzed by one-way ANOVA and Newman-Keuls’s post hoc test (p < 0.05); n = 6 mice
per group
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microbial shift due to an increased in gram-negative bac-
teria accompanied a reduction in bacterial diversity in IBD
patients, and this led to abnormalities in the inflammatory
process [39]. In the present study, the analysis of various
alpha diversity indices indicated that a reduction in bacter-
ial diversity occurred in the DSS group compared to the
control and SQE groups. In addition, the gut microbial
communities of the DSS group were characterized by a
clustered distance to the control group. The latter result is
consistent with the results of previous studies where micro-
bial divergence manifested as relative abundance shift in
cases of IBD [39, 40]. However, in the present study, SQE
supplementation recovered the bacterial diversity of the gut
and greater clustering of the gut microbial communities
close to the control group was observed compared to the
DSS group. Taken together, these results suggest that SQE
may help the gut microbiota to maintain their composition,
community, microbial evenness, and richness.
Interactions between gut microbiota and the host im-
mune system play an important role in the development
of a host’s immune system [41]. Generally, the compos-
ition of gut microbiota remains stable during adulthood,
and it can undergo dynamic changes in response to
environmental stresses or diet. Such alterations in
composition may influence health or disease risk [42].
The taxonomic compositions of the gut microbiota in
humans is similar to that observed in mice at the
phylum level [43]. Dysbiosis in patients with IBD has
been characterized as an increase in the ratio of Bacter-
oidetes/Firmicutes [28, 44]. In the present study, the ra-
tio of Bacteroidetes/Firmicutes was significantly higher
in the DSS group than in the control group, whereas this
ratio in the SQE group was similar to that of the control
group. It was also observed that the proportion of Firmi-
cutes was significantly decreased following DSS treat-
ment, yet the proportion recovered to control levels
following SQE supplementation. The Firmicutes phylum




Bacteroides acidifaciens 0.48 ± 0.41 a 18.54 ± 9.75 b 9.53 ± 6.55 a
Bacteroides sartorii 7.03 ± 10.51 6.22 ± 8.79 0.19 ± 0.19
Clostridium cocleatum 0.17 ± 0.13 a 9.43 ± 3.84 b 3.73 ± 4.21 a
Mucispirillum schaedleri 1.38 ± 1.66 1.64 ± 1.56 2.72 ± 2.98
Enterobacter xiangfangensis 0.01 ± 0.02 3.38 ± 6.37 0.04 ± 0.05
Akkermansia muciniphila 0 ± 0 1.24 ± 1.84 2.51 ± 4.24
Romboutsia ilealis 0 ± 0 1.17 ± 2.87 2.08 ± 4.32
Lachnospiraceae_uc_s 1.41 ± 0.47 0.25 ± 0.29 1.47 ± 1.75
Bacteroides_uc 0.30 ± 0.09 a 1.85 ± 1.18 b 0.73 ± 0.38 a
Butyricimonas virosa 0.45 ± 0.17 0.47 ± 0.30 0.38 ± 0.19
Ruminococcaceae_uc_s 0.54 ± 0.49 0.07 ± 0.06 0.27 ± 0.23
Lactococcus lactis subsp 0.41 ± 0.32 0.23 ± 0.19 0.15 ± 0.11
Values are mean ± SD
Significantly different by one – way ANOVA and Newman-Keuls’s post hoc test
among the three groups (p < 0.05); n = 6 mice per group
abFor a given column, data not sharing a common superscript letter significantly differ
Table 3 Composition of fecal microbiota in DSS – induced colitis mouse modelc
Phylum Genus Control DSS SQE
Firmicutes Pseudoflavonifractor 4.83 ± 0.82 2.71 ± 1.32 6.19 ± 3.93
Clostridium_g6 0.17 ± 0.13 a 9.49 ± 3.85 b 3.75 ± 4.23 a
Acetatifactor 1.48 ± 1.42 1.31 ± 1.30 4.78 ± 3.55
Oscillibacter 1.68 ± 0.75 a 1.12 ± 0.76 a 4.44 ± 2.68 b
Hungatella 3.56 ± 1.07 a 0.82 ± 0.69 b 1.50 ± 1.28 b
Turicibacter 1.72 ± 3.57 1.61 ± 1.73 1.73 ± 2.48
Clostridium_g21 1.51 ± 0.59 0.75 ± 0.44 1.78 ± 1.44
Romboutsia 0 ± 0 1.20 ± 2.93 2.09 ± 4.35
Lachnospiraceae_uc 1.41 ± 0.47 0.25 ± 0.29 1.47 ± 1.75
Roseburia 0.17 ± 0.08 0.11 ± 0.07 0.24 ± 0.17
Bacteroidetes Bacteroides 20.23 ± 6.55 a 41.64 ± 8.25 b 20.10 ± 6.43 a
Alloprevotella 4.07 ± 3.37 2.20 ± 2.76 3.19 ± 3.61
Alistipes 3.11 ± 1.12 a 0.31 ± 0.23 b 0.30 ± 0.16 b
Proteobacteria Enterobacter 0.02 ± 0.03 a 3.94 ± 7.40 b 0.04 ± 0.05 a
Parasutterella 0.01 ± 0.01 1.78 ± 3.55 0.04 ± 0.06
Deferribacteres Mucispirillum 1.38 ± 1.66 1.64 ± 1.56 2.72 ± 3.00
cCut-off: 1.0
Values are mean ± SD
Significantly different by one – way ANOVA and Newman-Keuls’s post hoc test among the three groups (p < 0.05); n = 6 mice per group
abFor a given column, data not sharing a common superscript letter significantly differ
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modulates the pH of the colonic and inhibits the growth
of pathogens by metabolizing short-chain fatty acids
(SCFAs) and producing butyrate in the intestinal mu-
cosa. Butyrate is a key energy source for epithelial cells
of the colon and it suppresses pro-inflammatory cyto-
kines in the gut [45]. At the class level, an increase in
Bacteroidia (phylum Bacteroidetes) and Gammaproteo-
bacteria, as well as a reduction in Clostridia (phylum
Firmicutes) was observed in the DSS group compared to
the control group. Gammaproteobacteria, a bacteria that
can induce acute intestinal inflammation, was also sig-
nificantly increased in the DSS group, thereby indicating
that changes in intestinal permeability and induction of
chronic systemic inflammation had occurred [46]. How-
ever, these changes in the composition of the microbial
community were reduced in the SQE group compared
to the DSS group, which suggested that SQE was able to
regulate a gut microbial community by modulating gut
inflammation.
In patients and experimental animal models with IBD,
the relative abundance of Lachnospiraceae was reduced
and the proportion of the Bacteroidaceae is relatively in-
creased [47]. Lachnospiraceae plays an important role in
fermenting SCFAs that derived from carbohydrates [48].
Another bacteria, Ruminococcaceae performs the first step
in carbohydrate metabolism where hydrogen is consumed
to butyrate. Microbial metabolisms of SCFAs is associated
with gut motility and intestinal transit time, as well as with
the function of histone deacetylases and the nervous
system [49]. In the present study, the compositional abun-
dances of Lachnospiraceae, Bacteroidaceae, and Rumino-
coccaceae, which mediate SCFA metabolism, were altered
in mice of the DSS group. In contrast, microbial dysbiosis
was improved in the SQE group compared with the DSS
group. Previously, it was reported that SQE facilitated gut
motility in the DSS-induced colitis mouse model [34], and
this explains the role of SQE in the metabolisms of SCFAs
and microbial composition related to intestinal function.
Enterobacteriaceae (genus Enterobacter), obligate anaer-
obic bacteria for the metabolism of high energy nutrients,
is present in greater number during inflammation [50]. In
the present study, an increase in the proportion of Entero-
bacteriaceae was consistently detected in the DSS group
compared with the control group, and this increase was
blocked with administration of SQE.
As presented above, a strong connection between gut
microbiota and the intestinal immune system has been
observed. Among the various microbacteria, Clostridium
(species Clostridium cocleatum) and Bacteroides (species
Bacteroides acidifaciens, Bacteroides_uc) have been re-
ported to induce the emission of regulatory T cells and
to reduce intestinal inflammation [51]. In the present
study, higher proportion of the Clostridium and Bacter-
oides were detected in the DSS group compared with to
the control group, and these increase suggest that pre-
vention of intestinal inflammation by specific groups of
commensal obligate anaerobic bacteria may mediate dir-
ect protective effects for pathogens. Furthermore, the
balance of microbial composition of species affects the
bile acid metabolism in the colon. In particular, Entero-
bacter, Bacteroides, and Clostridium absorb dietary fats,
facilitate lipid absorption, and maintain intestinal barrier
function [52]. Consequently, dysbiosis resulting from in-
testinal inflammation can affect the function of bacteria
and the other metabolic processes.
Many polyphenols contribute to important biological ac-
tivities, including antioxidant, anticarcinogenic, and anti-
microbial activities that are associated with pathological
disease processes [53, 54]. In addition, most polyphenols
are consumed and ingested, after being metabolized by gut
microbiota, which leads to greater biological activity and in-
creased bioavailability compared with their predecessors
[55]. Furthermore, polyphenol intake may have a dir-
ect impact on the composition of gut microbiota and
the functionality and the growth of certain bacterial
species. For example, in the presence of phenolic
compounds, the Firmicutes/Bacteroidetes ratio in the
microbiota of obese individuals was found to be al-
tered, and polyphenol-rich grape seed extract has
been found to contain a higher proportion of Lacto-
bacillus/Enterococcus bacteria [56, 57]. Several studies
have also shown that natural herbs and polyphenols
help to improve intestinal inflammation in colitis
model [58]. SQE has shown beneficial effects on col-
itis in previous studies. Moreover, the bioactive com-
ponent of SQE, tricin and p-coumaric acid, have
exhibited antioxidant, anti-inflammatory, and antican-
cer effects which remain to be investigated in relation
to gut microbiota [17, 18, 20, 34].
The identification of host and microbial interactions
in IBD patients, as well as a greater understanding of
the role of the microbiome and the changes in its
composition that occur in the disease states of IBD,
should lead to the development of highly effective
and nontoxic targeted interventions to correct under-
lying abnormalities and induce sustained therapeutic
responses. Currently, broad spectrum antibiotics, pro-
biotics, and prebiotics are used to prevent and treat
IBD [59]. The present results suggest a possible role
for SQE and its various of polyphenols in the clinical
treatments of IBD via regulation of gut microbiota
dysbiosis and diversity. Moreover, the use of SQE
would represent a natural therapeutic strategy for IBD
patients. However, a clinical intervention trial is
needed to confirm the present results in IBD patients,
while additional research is needed to understand the
relationship between dietary polyphenols and gut
microbiota.
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Conclusions
The present study we demonstrated that DSS-induced
colitis changed the diversity of the intestinal microbial
composition and diversity led to an increase of inflam-
mation in colon. However, when SQE was administered
prior to the induction of colitis by DSS, microbial dys-
biosis was reduced. These results increase our under-
standing of the important role that gut microbacteria
have in maintaining intestinal homeostasis, and they also
support the natural therapeutic potential of SQE for
modulating dysbiosis in IBD.
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